Evolving Landscape of Biologic Therapy for Pediatric Psoriasis.
Dermatol Clin 2024 Jul; 42(3):377-386.

Abstract

Pediatric psoriasis is a chronic inflammatory skin condition. Current treatment modalities include topical medications, phototherapy, and systemic drugs, including biological agents. In cases of moderate-to-severe psoriasis recalcitrant to other therapies, biological therapies are often an attractive option given their dosing schedules, safety profiles, and need for less frequent laboratory monitoring, when compared with traditional systemic therapies. This article reviews biological treatment options approved for pediatric psoriasis and identifies others actively under investigation.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Do HWeill Cornell Medical College, New York, NY, USA.
Babbush Graber KDepartment of Dermatology, Weill Cornell Medicine, 1305 York Avenue, 9th Floor, New York, NY 10021, USA.
Chernoff KADepartment of Dermatology, Weill Cornell Medicine, 1305 York Avenue, 9th Floor, New York, NY 10021, USA.
Melnick LEDepartment of Dermatology, Weill Cornell Medicine, 1305 York Avenue, 9th Floor, New York, NY 10021, USA. Electronic address: Lam9192@med.cornell.edu.

MeSH

HumansPsoriasisChildAdalimumabBiological ProductsUstekinumabDermatologic AgentsBiological TherapyInfliximabAntibodies, Monoclonal, HumanizedEtanerceptAntibodies, MonoclonalRituximabInterleukin 1 Receptor Antagonist ProteinAlefaceptCertolizumab Pegol

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

38796269